The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
407
Total number of T-1-weighted Gd-enhanced lesions obtained with MRI at 4-week intervals for 26 weeks.
Time frame: 26 weeks
Total volume of Gd-enhanced lesions
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo once per day for 26 weeks
Tucson Clinical Site 133
Tucson, Arizona, United States
Aurora Clinical Site 132
Aurora, Colorado, United States
Fort Collins Clinical Site 123
Fort Collins, Colorado, United States
Fairfield Clinical Site 110
Fairfield, Connecticut, United States
Ormond Beach Clinical Site 129
Ormond Beach, Florida, United States
Sarasota Clinical Site 116
Sarasota, Florida, United States
Sarasota Clinical Site 117
Sarasota, Florida, United States
Northbrook Clinical Site 135
Northbrook, Illinois, United States
Fort Wayne Clinical Site 111
Fort Wayne, Indiana, United States
Indianapolis Clinical Site 121
Indianapolis, Indiana, United States
...and 76 more locations